Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Cells lacking Cbf11 and/or Mga2 display nutrient-responsive decrease in lipid droplet (LD) content. by Anna Marešová (14375187)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…<p>(a) Left: noise-evoked activity rates at different noise intensities for chronically tracked PPys cells in baseline and repeated stress conditions (<i>N</i> = 5 mice, <i>n</i> = 285 neurons, mean ± SE). …”

Map of Pakistan with marked Punjab province. by Sumaira Sumaira (21453523)

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

PLB is a target gene of miRNA 221. by Hongyu Li (1332669)

Mean values of physical parameters of rock samples. by Dengke Yang (842532)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: